Virtu Financial LLC bought a new stake in Eli Lilly and Co (NYSE:LLY) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 35,485 shares of the company’s stock, valued at approximately $2,997,000.
A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Gradient Investments LLC acquired a new stake in shares of Eli Lilly and during the fourth quarter worth about $103,000. Acrospire Investment Management LLC lifted its position in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and during the second quarter worth about $128,000. San Francisco Sentry Investment Group CA acquired a new stake in shares of Eli Lilly and during the second quarter worth about $129,000. Finally, Front Row Advisors LLC acquired a new stake in shares of Eli Lilly and during the fourth quarter worth about $137,000. 76.20% of the stock is currently owned by institutional investors.
LLY has been the topic of several analyst reports. Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a report on Tuesday, January 16th. Goldman Sachs Group cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and raised their target price for the company from $86.98 to $95.00 in a report on Tuesday, January 16th. Argus raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and raised their target price for the company from $85.52 to $115.00 in a report on Friday, January 5th. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 5th. Finally, Bank of America reduced their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, February 1st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $92.02.
Eli Lilly and Co (NYSE LLY) opened at $78.97 on Friday. The company has a market cap of $86,953.47, a P/E ratio of 18.45, a price-to-earnings-growth ratio of 1.47 and a beta of 0.23. Eli Lilly and Co has a one year low of $73.69 and a one year high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.95 earnings per share. equities research analysts anticipate that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.85%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is currently -1,124.94%.
WARNING: “Virtu Financial LLC Buys New Stake in Eli Lilly and Co (LLY)” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2018/02/18/virtu-financial-llc-buys-new-stake-in-eli-lilly-and-co-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.